{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-22-000003","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.747055+00:00","generated_at":"2026-06-27T19:14:12.751745+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Exagen provides AVISE RADR presentation; no material operational or financial news","bullets":["Exagen released updated investor presentation highlighting its AVISE RADR test for rheumatoid arthritis drug response.","Presentation dated January 10, 2022, focuses on the test's ability to predict drug response in RA patients.","Company did not disclose any new financial results, guidance, or material events."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-22-000003","json":"https://secwatch.observer/filing/0001274737-22-000003.json","markdown":"https://secwatch.observer/filing/0001274737-22-000003.md","text":"https://secwatch.observer/filing/0001274737-22-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473722000003/0001274737-22-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473722000003/exdx-20220110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:14:12.751745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}